Nilotinib (Tasigna, NovartisPharmaceuticals), sanctioned by theUnited States Food and Drug Administration (FDA) in 2007, is a second-generationtyrosine kinase inhibitor (TKI) meticulously engineered to antagonizeaberrant BCR-ABL (Breakpoint Cluster Region-Abelson) fusion protein.1−3 Nilotinib, prescribed for specific forms of chronic myelogenousleukemia (CML) associated with the Philadelphia chromosome, demonstrates30-fold greater effectiveness against CML cells compared to Imatinib.Nilotinib exhibits superior binding affinity and selectivity for theBCR-ABL kinase in comparison to Imatinib. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.